PE20090706A1 - Composiciones farmaceuticas liofilizadas - Google Patents

Composiciones farmaceuticas liofilizadas

Info

Publication number
PE20090706A1
PE20090706A1 PE2008001634A PE2008001634A PE20090706A1 PE 20090706 A1 PE20090706 A1 PE 20090706A1 PE 2008001634 A PE2008001634 A PE 2008001634A PE 2008001634 A PE2008001634 A PE 2008001634A PE 20090706 A1 PE20090706 A1 PE 20090706A1
Authority
PE
Peru
Prior art keywords
cake
regulator
weight
amount
refers
Prior art date
Application number
PE2008001634A
Other languages
English (en)
Inventor
Thitiwan Buranachokpaisan
Wenlei Jiang
Wei-Qin Tong
Joseph Lawrence Zielinski
Jiahao Zhu
Hans-Peter Zobel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40005335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090706(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20090706A1 publication Critical patent/PE20090706A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UN HIDROXAMATO TAL COMO N-HIDROXI-3-[4-[[[2-(2-METIL-1H-INDOL-3-IL)-ETIL]-AMINO]-METIL]-FENIL]-2E-2-PROPENAMIDA; B) UN REGULADOR DE pH O COMPONENTE REGULADOR DE pH TALES COMO REGULADOR DE LACTATO, REGULADOR DE FOSFATO O COMBINACION DE AMBOS EN UNA CANTIDAD DEL 0.1% A 15% DEL PESO DE LA TORTA; C) UN AGENTE DE VOLUMEN TALES COMO SACAROSA, TREHALOSA, DEXTRANO, ENTRE OTROS EN UNA CANTIDAD DE 50% A 99.9% DEL PESO DE LA TORTA; D) UN QUELANTE/ANTIOXIDANTE TAL COMO EDTA DISODICA EN UNA CANTIDAD DE 0% A 5% DEL PESO DE LA TORTA. SE REFIERE TAMBIEN AL PROCESO DE LIOFILIZACION PARA ELABORAR UNA TORTA FARMACEUTICAMENTE ACEPTABLE DE ADMINISTRACION ORAL Y PARENTERAL.DICHA LIOFILIZACION MEJORA LA ESTABILIDAD TANTO FISICA COMO QUIMICA DEL COMPUESTO TERAPEUTICO
PE2008001634A 2007-09-20 2008-09-18 Composiciones farmaceuticas liofilizadas PE20090706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97383007P 2007-09-20 2007-09-20

Publications (1)

Publication Number Publication Date
PE20090706A1 true PE20090706A1 (es) 2009-07-15

Family

ID=40005335

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001634A PE20090706A1 (es) 2007-09-20 2008-09-18 Composiciones farmaceuticas liofilizadas

Country Status (20)

Country Link
US (1) US20100331387A1 (es)
EP (1) EP2205222A1 (es)
JP (1) JP2010540445A (es)
KR (1) KR20100059887A (es)
CN (1) CN101801345A (es)
AR (1) AR068822A1 (es)
AU (1) AU2008302273A1 (es)
BR (1) BRPI0817118A2 (es)
CA (1) CA2696914A1 (es)
CL (1) CL2008002786A1 (es)
CO (1) CO6270207A2 (es)
EC (1) ECSP10010039A (es)
GT (1) GT201000062A (es)
MA (1) MA31744B1 (es)
MX (1) MX2010002970A (es)
PE (1) PE20090706A1 (es)
RU (1) RU2010115262A (es)
TN (1) TN2010000097A1 (es)
TW (1) TW200930416A (es)
WO (1) WO2009039226A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018069901A2 (pt) * 2016-03-31 2019-02-05 Midatech Ltd aduto de ciclodextrina-panobinostat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
PL1663978T3 (pl) * 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US20060270730A1 (en) * 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
JP2010515740A (ja) * 2007-01-10 2010-05-13 ノバルティス アーゲー デアセチラーゼインヒビター製剤
EP2120900A2 (en) * 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer

Also Published As

Publication number Publication date
CN101801345A (zh) 2010-08-11
CL2008002786A1 (es) 2009-05-15
RU2010115262A (ru) 2011-10-27
AR068822A1 (es) 2009-12-09
MA31744B1 (fr) 2010-10-01
TW200930416A (en) 2009-07-16
ECSP10010039A (es) 2010-04-30
GT201000062A (es) 2012-03-30
BRPI0817118A2 (pt) 2019-09-24
WO2009039226A1 (en) 2009-03-26
CA2696914A1 (en) 2009-03-26
JP2010540445A (ja) 2010-12-24
US20100331387A1 (en) 2010-12-30
EP2205222A1 (en) 2010-07-14
KR20100059887A (ko) 2010-06-04
AU2008302273A1 (en) 2009-03-26
CO6270207A2 (es) 2011-04-20
MX2010002970A (es) 2010-04-01
TN2010000097A1 (en) 2011-09-26

Similar Documents

Publication Publication Date Title
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
MX2010005342A (es) Compuestos indola y metodos para tratar el dolor visceral.
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
MX2010003923A (es) Formulacion farmaceutica de valsartan.
EA201071094A1 (ru) Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
CO6241104A2 (es) "composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea o sales de la misma para la inhibicion de la agregacion de plaquetas inducidas por adp"
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
MX2010005824A (es) Derivados de aminotiazol.
GEP20146177B (en) Pyrazole compounds as crth2 antagonists
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
BR112014011981A2 (pt) formulações farmacêuticas
EA201300539A1 (ru) Твердая композиция для приема внутрь (варианты), способ терапевтической или нетерапевтической профилактики желудочно-кишечных расстройств или поддержания здорового состояния желудочно-кишечного тракта с ее помощью (варианты) и упаковка, ее содержащая
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
CO6341624A2 (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
PH12017502252B1 (en) Stable pharmaceutical composition for oral administration
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
PE20091560A1 (es) Comprimido de desintegracion oral

Legal Events

Date Code Title Description
FC Refusal